FOXO3 and Cognitive impairment: However, immunohistochemical staining suggests that brain tissue from TBI patients expresses higher levels of Foxo3a compared to non-TBI populations, and these preliminary clinical trials demonstrate the potential of Foxo3a as a biomarker for diagnosing cognitive impairment.